AIM AIM ImmunoTech

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

OCALA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent No. 12,102,649, covering both compositions and methods comprising the Company’s drug Ampligen® in the treatment of endometriosis, a painful chronic condition that affects nearly 10% of women of reproductive age, or approximately 6.5 million women in the United States.

Endometriosis is a disease in which tissue similar to the lining of the uterus grows outside the uterus, causing severe pelvic pain and making it difficult or impossible to become pregnant. It can cause inflammation and infertility, and symptoms such as intense menstrual cramps, severe pelvic pain and chronic fatigue, all of which can significantly impact quality of life. Despite its prevalence, treatment options are limited, and many women experience years of misdiagnosis.

The patented method involves the administration of a therapeutically effective amount of a pharmaceutical composition containing AIM’s proprietary double-stranded RNA products.

The patent’s claims describe a unique class of therapeutic double-stranded RNAs (e.g., tdsRNA, Ampligen®, rugged dsRNA) which are key components in these potentially groundbreaking treatment methods and compositions. The versatile administration options offer flexibility for patient-specific needs and care. The patent also covers treatments targeting recurrent endometriosis and includes options for co-administration with interferons, including well-known types such as alpha and beta interferons.

Patients with endometriosis also are at more than four times the risk of developing ovarian cancer than are people without endometriosis, according to a recent article in . As we have previously announced, Ampligen has also shown positive results as part of a combination therapy in the treatment of advanced recurrent ovarian cancer.

Read more:

Robert Edwards, MD, a world-renowned expert in women’s reproductive health and Chair of Ob/Gyn/RS at the University of Pittsburgh Medical Center, Magee-Womens Hospital, stated: “Endometriosis is a chronic disease that threatens the fertility and wellbeing of greater than 10% of the population, but total incidence is not known. Effective treatment now involves some form of estrogen deprivation or surgery, both of which have serious side effects and fertility risks themselves. A medical therapy that relieves symptoms and abates the inflammatory response would be a significant breakthrough in treatment options. At UPMC we have conducted an extensive clinical evaluation of Ampligen in recurrent ovarian cancer with positive results. Ampligen’s safety profile is well developed and Ampligen has been generally well tolerated.”

AIM Chief Executive Officer Thomas K. Equels commented, "This patent is a significant milestone for AIM, not only strengthening our intellectual property portfolio, but also expanding our potential to provide life-changing therapies for women suffering from endometriosis. With the global focus on women's health, we are excited about the possibilities this new treatment presents. At AIM, our goal is to make a difference by improving the quality of life for women suffering from endometriosis."

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit  and connect with the Company on , , and .

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date does not guarantee that Ampligen will be approved as a therapy for endometriosis or ovarian cancer. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Photos accompanying this announcement are available at: 



Investor Contact:

JTC Team, LLC

Jenene Thomas

(908) 824-0775

 
EN
03/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM ImmunoTech

 PRESS RELEASE

AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswel...

AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that data were published on Roswell Park Comprehensive Cancer Center’s Phase 1 study evaluating AIM ImmunoTech’s drug Ampligen® (also known as rintatolimod) as a component of a chemokine-modulating (CKM) regimen in early-stage triple-negative breast cancer (TNBC). Results of the study were reported in . “We are very excited with the...

 PRESS RELEASE

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provid...

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update – Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with positive clinical trial data, underscoring big pharma collaboration and commercialization opportunities – Company to host conference call and webcast today, November 15th, at 8:30 AM ET OCALA, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) has reported its financial r...

 PRESS RELEASE

AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on Nove...

AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast OCALA, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a to discuss the Company’s Q3 2024 operational and financial results on Friday, November 15, 2024 at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference cal...

 PRESS RELEASE

AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, P...

AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC Live webcast fireside chat on Wednesday, October 16th at 12:30 PM ET OCALA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), announced today that Tom Equels, Chief Executive Officer of AIM, will participate in a fireside chat at the on October 16, 2024 at 12:30 PM ET. Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive d...

 PRESS RELEASE

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of ...

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis OCALA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent No. 12,102,649, covering both compositions and methods comprising the Company’s drug Ampligen® in the treatment of endometriosis, a painful chronic condition that affects nearly 10% of women of reproductive age, or approximately 6.5 million women in the United States. Endometriosis is a disease in which tiss...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch